More than one-third of patients do not tell their physicians all of the prescription and over-the-counter medications that they are taking.
More than one-third of patients do not tell their physicians all of the prescription and over-the-counter medications that they are taking, according to a recent survey sponsored by Milwaukee-based Schwarz Pharma.
In a survey of 1,000 adults, 38% reported that they did not always give their physicians a complete list of all medications taken. And although more women (70%) than men (53%) informed their doctor of their medications, and the quality of patient-physician communication improved with the patient's age, 58% of all adults who reported taking prescription medication reported minor side effects, such as dizziness, nausea or shortness of breath.
"Some incidence of side effects with any prescription or even over-the-counter medication is inherent," said Klaus Veitinger, president of Schwarz Pharma. "The more important issueâ¦is the potential for adverse interaction resulting in side effects when patients are taking multiple prescription and/or over-the-counter medicines."
The importance of fully disclosing medication regimens increases with a patient's age, as many patients find themselves taking multiple prescription products to combat a variety of age-related afflictions.
Based on its survey results, Schwarz Pharma recommended the following:
• Patients should carry a list of the medications they are taking, both prescription and over-the-counter.
• Patients should make certain the list is included with their medical records and is updated to reflect changes.
• Patients need to ask their physicians and pharmacists about possible side effects and adverse reactions when they are prescribed a new medication.
Schwarz Pharma also recommended that patients, physicians and pharmacists carefully read product literature. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.